全文获取类型
收费全文 | 2431720篇 |
免费 | 177011篇 |
国内免费 | 5386篇 |
专业分类
耳鼻咽喉 | 32049篇 |
儿科学 | 81224篇 |
妇产科学 | 67085篇 |
基础医学 | 347483篇 |
口腔科学 | 70292篇 |
临床医学 | 219700篇 |
内科学 | 471428篇 |
皮肤病学 | 55130篇 |
神经病学 | 190244篇 |
特种医学 | 92102篇 |
外国民族医学 | 526篇 |
外科学 | 366849篇 |
综合类 | 56863篇 |
现状与发展 | 4篇 |
一般理论 | 869篇 |
预防医学 | 184392篇 |
眼科学 | 57625篇 |
药学 | 177132篇 |
9篇 | |
中国医学 | 5781篇 |
肿瘤学 | 137330篇 |
出版年
2019年 | 18763篇 |
2018年 | 27268篇 |
2017年 | 20790篇 |
2016年 | 23020篇 |
2015年 | 26177篇 |
2014年 | 36262篇 |
2013年 | 53944篇 |
2012年 | 73452篇 |
2011年 | 77759篇 |
2010年 | 46163篇 |
2009年 | 43238篇 |
2008年 | 72445篇 |
2007年 | 77140篇 |
2006年 | 77837篇 |
2005年 | 74598篇 |
2004年 | 72382篇 |
2003年 | 68926篇 |
2002年 | 66582篇 |
2001年 | 122096篇 |
2000年 | 125022篇 |
1999年 | 103988篇 |
1998年 | 27937篇 |
1997年 | 24682篇 |
1996年 | 24712篇 |
1995年 | 23712篇 |
1994年 | 21827篇 |
1993年 | 20263篇 |
1992年 | 80060篇 |
1991年 | 77626篇 |
1990年 | 75220篇 |
1989年 | 72461篇 |
1988年 | 65846篇 |
1987年 | 64955篇 |
1986年 | 61076篇 |
1985年 | 58260篇 |
1984年 | 43067篇 |
1983年 | 36524篇 |
1982年 | 21067篇 |
1981年 | 18860篇 |
1979年 | 38589篇 |
1978年 | 27149篇 |
1977年 | 23126篇 |
1976年 | 21597篇 |
1975年 | 22710篇 |
1974年 | 27550篇 |
1973年 | 26496篇 |
1972年 | 24520篇 |
1971年 | 22701篇 |
1970年 | 21117篇 |
1969年 | 19763篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
J. Rodríguez-Carrio A. Martínez-Zapico I. Cabezas-Rodríguez L. Benavente Á.I. Pérez-Álvarez P. López J.B. Cannata-Andía M. Naves-Díaz A. Suárez 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(2):135-143
Background and aims
Since accelerated atherosclerosis has been reported in systemic lupus erythematosus (SLE), predictive biomarkers of cardiovascular disease (CVD) are needed. Among non-traditional risk factors, bone mineral density (BMD) has been related to CVD. However, its role in SLE remains controversial. This study aims to analyze the associations of subclinical atherosclerosis with traditional and non-traditional CV risk factors.Methods and results
In a cross-sectional study, atherosclerosis burden was compared between 112 female SLE patients and 31 controls. Plaque number and carotid intima-media wall thickness (cIMT) were assessed by ultrasonography. In a retrospective study, BMD determinations obtained 5-years before the ultrasonography assessment were analyzed in a subgroup of 62 patients. Plaque frequency was increased in SLE, even in patients without CV events or carotid wall thickening. cIMT was increased in patients with CVD, positively correlated with body mass index (BMI). Interestingly, a paradoxical effect of BMI on carotid parameters was observed. Whereas underweight patients (BMI < 20) showed increased prevalence of carotid plaques with low cIMT, those with BMI > 30 showed higher cIMT and plaque burden. Overweight patients (25 < BMI<30) exhibited both elevated cIMT and plaque number. BMI was an independent predictor of BMD. In our retrospective study, patients with either clinical or subclinical CVD exhibited lower BMD levels than their CV-free counterparts. A low lumbar spine BMD independently predicted CVD development after adjusting for confounders.Conclusion
SLE was associated with a higher subclinical atherosclerosis burden, a bimodal effect being observed for BMI. Decreased BMD can be a CV risk biomarker in SLE. 相似文献22.
23.
Chronic transplant dysfunction is a complex dynamic pathogenic process. Clinically, a decrease in glomerular filtration rate (GFR) becomes apparent leading to chronic renal insufficiency and dialysis or death from cardiovascular events. Chronic transplant dysfunction can develop into a chronic alIograft nephropathy (CAN) as a specific entity with dynamic progression. CAN includes a collection of immunologic and non-immunologic factors, rejection, ischemia time, donor and recipient characteristics and toxicity of calcineurin inhibitors. Despite improvements in immunosuppression, the long-range prognosis of renal allografts has not improved. Whether modern immunosuppressive concepts with reduction or avoidance of calcineurin inhibitors and a therapy based on antimetabolites, such as mycophenolate or mTOR-inhibitors could lead to a prolongation of transplant survival, remains to be seen. 相似文献
24.
25.
D B Irving J L Cook H B Menz 《Journal of Science and Medicine in Sport》2006,9(1-2):11-22; discussion 23-4
26.
A Kotsiou M Tsamouri S Anagnostopoulou M Tzivras E Vairactaris C Tesseromatis 《European journal of drug metabolism and pharmacokinetics》2006,31(2):97-101
Liver disease alters the pharmacokinetic and pharmacodynamic properties of hepatically eliminated drugs. The main factors influenced are plasma albumin levels, enzyme balance (induction & inhibition) and drug binding to tissue proteins. The influence of lidocaine on serum, heart and liver propranolol levels in Wistar rats after liver injury induced by carbon tetrachloride CCl4 0.4 ml/kg x 2/wkl, was investigated. 40 male Wistar rats were divided into four groups (I, II, III, IV; n=10), Group I animals received only propranolol (labelled + cold substance) 40 mg/kg/12 h p.o., group II propranolol plus lidocaine in a single dose of 4mg/kg s.c., group III was treated with CCl4 for 6 weeks and received propranolol x2 at the same dosage as group I, while group VI was treated with CCl4 and the same drug dosage as group II. The simultaneous administration of H3-propranolol and lidocaine increased propranolol levels in the serum and tissues. The liver in damaged animals showed an increase of propranolol level under lidocaine co-administration, probably due to CCl4 induced liver enzyme activity, resulting in a rapid propranolol metabolism or to competition between both drug protein binding sites. The increased propranolol levels in the heart after lidocaine administration were probably due to attributed to its high affinity for heart tissue. Consequently, as regards the therapeutic approach for patients with liver disease receiving propranolol their propranolol dosage should be reduced when lidocaine is co-administered. 相似文献
27.
A-C Koschker M Fassnacht S Hahner D Weismann B Allolio 《Experimental and clinical endocrinology & diabetes》2006,114(2):45-51
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumour with a poor prognosis. Patients present with signs of steroid hormone excess (e.g., Cushing's syndrome) or symptoms due to an abdominal mass. DIAGNOSIS: In case of an adrenal mass, hormonal workup before surgery is required for differential diagnosis, perioperative management, and for follow-up. The imaging of choice is CT or MRI with MRI being of additional use when invasion of big vessels is suspected. Apart from that, the use of 18-FDG-PET is becoming increasingly established. TREATMENT: Surgical resection is the therapeutic option of choice in stages 1 - 3. In stage 4, the adrenolytic compound mitotane is part of the first-line treatment, but often needs to be combined with cytotoxic chemotherapy. Most patients will eventually have a recurrence, so adjuvant treatment (mitotane/tumour bed radiation) has to be considered in high risk patients, even if randomized controlled trials on adjuvant treatment are still lacking. STRUCTURAL PROGRESS: Several national and European structures have recently been established in order to increase our knowledge of ACC, improve therapeutic options and diagnostic procedures, and promote research. GANIMED, as a Germany-wide network of experts on adrenal diseases, has been founded allowing for improved gathering of data and joint studies. ENSAT (European Network for the Study of Adrenal Tumours) has been brought to life, aiming at European standards for therapy, diagnosis and tumour banking. Since 2003, patients can be enrolled in the German ACC Registry. France and Italy have also developed a central registry to collect nationwide data from patients with ACC. For the first time, patients with metastatic/unresectable ACC can participate in a prospective controlled randomized trial comparing two different cytotoxic chemotherapy regimes (FIRM-ACT). 相似文献
28.
B Dederichs M Dietlein B Jenniches-Kloth M Schmidt P Theissen D Moka H Schicha 《Experimental and clinical endocrinology & diabetes》2006,114(7):366-370
BACKGROUND: Radioiodine therapy (RIT) combined with glucocorticoids is an effective therapy for Graves' disease, but it is debatable whether glucocorticoids should be applied in patients without Graves' ophthalmopathy (GO). METHODS: The effect of 0.4 - 0.5 mg prednisone every second day over a period of 5 weeks after RIT was monitored over a follow-up period of at least 12 months after RIT. A questionnaire was sent to 186 consecutive patients without GO concerning eye symptoms after RIT. 148 patients (80 %) answered. If eye symptoms had occurred after RIT, additional clinical examination was carried out at our outpatient clinic. The primary endpoint was the absence or onset of GO within the first year after RIT. RESULTS: Within 12 months after RIT the examination confirmed GO in 5 out of 148 patients (3.4 %). In all cases the symptoms were transient. No adverse reaction to the use of prednisone after RIT was noted. CONCLUSIONS: The risk of new GO in the first year after RIT was low and the clinical course of GO was mild when RIT was combined with a low-dose glucocorticoid regimen. Preventive administration of glucocorticoids can therefore be recommended in patients with Graves' disease even without evident GO. 相似文献
29.
M Vitacca M Paneroni L Bianchi E Clini A Vianello P Ceriana L Barbano B Balbi S Nava 《The European respiratory journal》2006,27(2):343-349
The present study compared four different sites and conditions for the measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) in 38 spontaneous breathing tracheotomised patients. Of the patients, 28 had chronic obstructive pulmonary disease (COPD). The four different conditions were: 1) through a cuff inflated cannula (condition A); 2) through the mouth with a deflated cannula (condition B); 3) through the mouth with a phonetic uncuffed cannula (condition C); and 4) through the mouth after stoma closure (condition D). Five trials in each condition were performed using a standardised method. The measurement of both MIP and MEP differed significantly depending on the condition of measurement. MIP taken in condition A was significantly higher when compared with conditions B, C and D. MEP in condition A was significantly higher when compared with condition B and D. In condition A the highest frequency of the best measurement of MIP and MEP was observed at the fourth and fifth effort, respectively. The same results were obtained after the selection of only COPD patients. In conclusion, respiratory muscle assessment differs significantly depending on measurement condition. Measurement through inflated cannula tracheotomy yields higher values of both maximal inspiratory and maximal expiratory pressure. 相似文献
30.